After the recent announcement by the management that they will be launching Atorvastatin generics as per expected timelines, the stock price seems to have not reacted enough. Atorvastatin opportunity for Ranbaxy is being underplayed or the threat of a hefty fine by the USFDA is dominating investor sentiments. Ranbaxy has clearly stated that the fine is not going to be $1billion as speculated by the media, but would be lower. It would be difficult to estimate the fine for anybody, as there are no precedence’s for this.
However what we can certainly estimate is the opportunity from atorvastatin generics. There are primarily two reasons, why I think the magnitude of profits for Ranbaxy is going to be huge upto $1billion in profits
Full Story Continued on